Khosla Ventures leads Series A round for Prellis Biologics
San Francisco-based Prellis Biologics, a human tissue engineering company, has raised $8.7 million in Series A funding. Khosla Ventures led the round.
1 August 2019•1 min read
San Francisco-based Prellis Biologics, a human tissue engineering company, has raised $8.7 million in Series A funding. Khosla Ventures led the round.
